Thrombotic microangiopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:16:11 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Thrombotic microangiopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-urokinase-catalytic-domain-fused-with-a-single-chain-antibody-against-von-willebrand-factor-in-patients-with-immune-mediated-thrombotic-thrombocytop/ Wed, 29 Apr 2026 15:09:19 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-urokinase-catalytic-domain-fused-with-a-single-chain-antibody-against-von-willebrand-factor-in-patients-with-immune-mediated-thrombotic-thrombocytop/ This study focuses on diseases known as Thrombotic Microangiopathies, a group of conditions where small blood vessels become damaged and blocked by tiny blood clots. One specific type of this condition is Immune-Mediated Thrombocytopenic Purpura, a rare disorder where the body’s immune system mistakenly attacks and destroys platelets, which are the cells responsible for helping blood clot. The research aims to evaluate the safety and effectiveness of an experimental drug called TGD001. This medication is a specialized protein designed to target certain factors in the blood that contribute to the formation of these harmful clots.

The treatment involving TGD001 is administered through an intravenous method, which means it is delivered directly into a vein using a solution for injection. During the study, participants will receive the medication to observe how the body reacts and to see if it helps manage the symptoms of the disease. The process involves monitoring how the drug moves through the body and checking for any side effects or changes in blood cell levels over time.

]]> Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant https://clinicaltrials.eu/trial/study-on-ravulizumab-for-patients-with-thrombotic-microangiopathy-after-stem-cell-transplant/ Wed, 29 Apr 2026 14:48:00 +0000 https://clinicaltrials.eu/trial/study-on-ravulizumab-for-patients-with-thrombotic-microangiopathy-after-stem-cell-transplant-2/ This clinical trial is focused on studying a condition called Thrombotic Microangiopathy (TMA), which can occur after a Hematopoietic Stem Cell Transplant (HSCT). TMA is a serious condition that affects the small blood vessels and can lead to complications such as low platelet counts, anemia, and organ damage. The study is testing a treatment called Ravulizumab, which is given as an infusion into a vein. This treatment is being compared to a placebo to see how effective it is in treating TMA in adults and adolescents who have undergone HSCT.

The purpose of the study is to assess how well Ravulizumab works in treating TMA. Participants in the study will receive either Ravulizumab or a placebo. The study will last for several months, during which participants will receive regular infusions and have their health monitored closely. The study aims to see if Ravulizumab can help improve symptoms of TMA and prevent further complications.

Throughout the study, participants will be monitored for changes in their health, including any improvements in organ function and overall survival. The study will also track how quickly participants respond to the treatment and if there are any relapses of TMA. This research is important for finding better ways to treat TMA in patients who have had a stem cell transplant.

]]> Study of Pegcetacoplan (APL-2) in Patients with Transplant-associated Thrombotic Microangiopathy After Stem Cell Transplantation https://clinicaltrials.eu/trial/study-of-apl-2-for-patients-with-transplant-associated-thrombotic-microangiopathy-after-stem-cell-transplantation/ Wed, 29 Apr 2026 14:29:02 +0000 https://clinicaltrials.eu/trial/study-of-apl-2-for-patients-with-transplant-associated-thrombotic-microangiopathy-after-stem-cell-transplantation/ This study focuses on patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA), a condition that can occur after receiving a hematopoietic stem cell transplant. TA-TMA is a serious complication that affects small blood vessels and can cause damage to various organs. The study will test a medication called pegcetacoplan (also known as APL-2) in patients who have developed this condition after their transplant.

The purpose of this research is to understand how the body processes pegcetacoplan and to evaluate if it is safe and well-tolerated by patients with TA-TMA. The medication works by targeting part of the body’s immune system known as the complement system, which plays a role in this condition.

This is an open-label study where all participants will receive pegcetacoplan. The study will monitor various aspects of patients’ health, including blood tests and organ function, for 24 weeks. The research will look at how the medication affects certain proteins in the blood and whether it helps improve the symptoms of TA-TMA, including kidney function, blood cell counts, and other health measures.

]]> Study of Narsoplimab for Children with High-Risk Blood Vessel Damage After Stem Cell Transplant https://clinicaltrials.eu/trial/study-of-narsoplimab-for-children-with-high-risk-blood-vessel-damage-after-stem-cell-transplant/ Wed, 29 Apr 2026 14:28:41 +0000 https://clinicaltrials.eu/trial/study-of-narsoplimab-for-children-with-high-risk-blood-vessel-damage-after-stem-cell-transplant/ This clinical trial is focused on studying a condition called Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy (HSCT-TMA), which can occur in children who have undergone a stem cell transplant. This condition involves damage to small blood vessels, leading to problems such as low platelet counts and other complications. The study is testing a treatment called Narsoplimab, which is given as a solution for injection. Narsoplimab is being investigated to see if it can help improve the survival rate and overall health of children affected by this condition.

The purpose of the study is to evaluate the effectiveness and safety of Narsoplimab in children aged 28 days to 18 years who have been diagnosed with high-risk HSCT-TMA. Participants in the study will receive Narsoplimab through an intravenous injection, which means it is administered directly into a vein. The study will monitor the participants over a period to assess their survival rate 100 days after the diagnosis of HSCT-TMA, as well as other health outcomes over a longer period.

Throughout the study, researchers will also look at how the body processes Narsoplimab and any potential side effects. The study aims to gather important information on how well Narsoplimab works in treating HSCT-TMA and its safety in pediatric patients. This research could provide valuable insights into managing this serious condition in children who have undergone a stem cell transplant.

]]>